Breast cancer early detection is crucial for improving patient outcomes. The Institut Catala de la Salut (ICS) has launched‘ the DigiPatICS project to develop and implement artificial intelligence ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

HER2/neu Expression and Hormonal Therapy in Early Breast Cancer: Can Muddy Waters Become Clear? Authors: Gianluigi Ferretti, Serena Di Cosimo, Diana Giannarelli, Paolo Carlini, Paola Papaldo, Andrea ...

Small-molecule irreversible tyrosine kinase inhibitors as high potent agents have led to improvements in disease-free and overall survival in patients with HER2-amplified cancer. The approved ...

There were no cases of HER2 positivity among patients with gliomas, sarcomas, small cell lung cancer, gastrointestinal stromal tumors, thyroid carcinoma, uterine sarcoma, thymic carcinoma, and Merkel ...

Rates of HER2 expression are examined and trastuzumab is tested in combination with paclitaxel and carboplatin in patients with resistant advanced ovarian cancer.

“The Series D financing represents further endorsement of Neuron23’s industry-leading approach, which leverages state-of-the-art precision medicine and patient identification to deliver NEU ...

Objective Neratinib plus capecitabine (Ner+Cap) were proved to be clinically beneficial as a third-line treatment for women with human epidermal growth factor receptor-2 (HER2) positive metastatic ...

Amplification of the human epidermal growth factor receptor 2 (HER2, Erb B2) gene leads to persistent activation of signaling pathways that enhance cell proliferation, resistance to apoptosis signals, ...

$2.25 Million Research Collaboration Focused on Understanding and Treating Lung Cancers Harboring HER2 Mutations; call for Requests for Proposals NEW YORK, June 17, 2025 /PRNewswire/ -- The Lung ...

This trial focused on patients with HER2-positive metastatic breast cancer who hadn't received any treatment other than a few with endocrine therapy for metastatic or advanced disease, and ...